Abstract:Synchrotron radiation offers a host of advanced properties, surpassing conventional laboratory sources with its high brightness, tunable phonon energy, photon beam coherence for advanced X-ray imaging, and a structured time profile, ideal for capturing dynamic atomic and molecular processes. However, these benefits come at the cost of operational complexity and expenses. Three decades ago, synchrotron radiation facilities, while technically open to all scientists, primarily served a limited community. Despite substantial accessibility improvements over the past two decades, synchrotron measurements still do not qualify as routine analyses. The intrinsic complexity of synchrotron science means experiments are pursued only when no alternatives suffice. In recent years, strides have been made in technology transfer offices, intermediate synchrotron-based analytical service companies, and the development of high-throughput synchrotron systems at various facilities, reshaping the perception of synchrotron science. This article investigates the practical application of synchrotron X-Ray Powder Diffraction (s-XRPD) techniques in pharmaceutical analysis. By utilizing concrete examples, we demonstrate how high-throughput systems have the potential to revolutionize s-XRPD applications in the pharmaceutical industry, rapidly generating XRPD patterns of comparable or superior quality to those obtained in state-of-the-art laboratory XRPD, all in less than 5 s. Additional cases featuring well-established pharmaceutical active ingredients (API) and excipients substantiate the concept of high throughput in pharmaceuticals, affirming data quality through structural refinements aligned with literature-derived unit cell parameters. Synchrotron data need not always be state-of-the-art to compete with lab-XRPD data. The key lies in ensuring user-friendliness, reproducibility, accessibility, cost-effectiveness, and the streamlined efforts associated with synchrotron instrumentation to remain highly competitive with their laboratory counterparts.

Drug design and synchrotron

Synchrotron radiation: A key tool for drug discovery

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Exploring high-throughput synchrotron X-Ray powder diffraction for the structural analysis of pharmaceuticals

Towards Structure-Based Protein Drug Design

Exploring serial crystallography for drug discovery

Protein X-ray Crystallography and Drug Discovery

Drug discovery and optimization based on the co-crystal structure of natural product with target

Predictive and Accelerated Formulation Design Using Synchrotron Methods

Research progress on architecture of dosage forms using synchrotron radiation X-ray microtomography

Using X-ray Diffraction Techniques for Biomimetic Drug Development, Formulation, and Polymorphic Characterization

An outlook on using serial femtosecond crystallography in drug discovery

Research on targeted drug design based on computer technology

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

In situ analysis of metallodrugs at the single-cell level based on synchrotron radiation technology

Design of Synchrotron for Proton FLASH Radiotherapy

Recent Trends in Drug Design and Discovery

X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?

Structure-based drug design: NMR-based approach for ligand-protein interactions.

Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery

Sequence-based drug design as a concept in computational drug design